Helus Pharma (Cybin Inc.) CEO to Participate in 29th Annual Milken Institute Global Conference

Cybin Inc. (operating as Helus Pharma) announced that its Interim Chief Executive Officer, Eric So, will participate in the 29th Annual Milken Institute Global Conference. Mr. So is scheduled to speak on a panel titled 'The Next Wave of Health Innovation' on May 4, 2026, in Los Angeles. Helus Pharma is a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions. The company's lead programs include HLP003, a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), which has received FDA Breakthrough Therapy Designation. Additionally, the company is developing HLP004, which is in Phase 2 trials for generalized anxiety disorder (GAD). The announcement serves primarily as a corporate update regarding executive participation at an industry event and does not contain new clinical data or regulatory updates.